These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2039989)

  • 1. Clinical pharmacology of deoxyspergualin in patients with advanced cancer.
    Muindi JF; Lee SJ; Baltzer L; Jakubowski A; Scher HI; Sprancmanis LA; Riley CM; Vander Velde D; Young CW
    Cancer Res; 1991 Jun; 51(12):3096-101. PubMed ID: 2039989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection.
    Ohlman S; Zilg H; Schindel F; Lindholm A
    Transpl Int; 1994; 7(1):5-10. PubMed ID: 8117404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
    Havlin KA; Kuhn JG; Koeller J; Boldt DH; Craig JB; Brown TD; Weiss GR; Cagnola J; Phillips J; Harman G
    Anticancer Drugs; 1995 Apr; 6(2):229-36. PubMed ID: 7795272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical antitumor activity and pharmacological properties of deoxyspergualin.
    Plowman J; Harrison SD; Trader MW; Griswold DP; Chadwick M; McComish MF; Silveira DM; Zaharko D
    Cancer Res; 1987 Feb; 47(3):685-9. PubMed ID: 3802074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
    Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper MA; Grasela D; Buzdar A; Valero V
    Cancer Res; 1995 Jul; 55(14):3060-7. PubMed ID: 7606728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
    Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of 15-deoxyspergualin in a canine renal allograft model of local immunosuppression.
    Gruber SA; Hughes SE; Xiao S; Perera S; Jayasankar V; Rosario AD; Singh J
    J Surg Res; 1997 Aug; 71(2):137-44. PubMed ID: 9299281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial and clinical pharmacology of elsamitrucin.
    Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
    Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
    Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP
    Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
    Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
    Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
    Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
    Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
    Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.